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Abstract: 
The distinction of complex atypical endometrial hyperplasia from endometrial 
adenocarcinoma is often problematic. Foci of back-to-back arrangement of glands or foci 
of cribriform arrangement of glands smaller than 2.1 mm in diameter are considered 
insufficient for the diagnosis of endometrial adenocarcinoma by some authors, and 
sufficient to be diagnosed as endometrial adenocarcinoma by other authors. We refer to 
these foci as endometrial Adenocarcinoma-in-situ. In this study we evaluated findings in 
subsequent hysterectomy in complex atypical endometrial hyperplasia patients with and 
without Adenocarcinoma-in-situ. Follow-up findings, including the presence or absence 
of endometrial adenocarcinoma in the hysterectomy specimen, the grade of the carcinoma 
and the depth of myometrial invasion were analyzed. Of the total 87 patients with 
complex atypical endometrial hyperplasia, thirty-three patients had Adenocarcinoma-in-
situ and 54 lacked Adenocarcinoma-in-situ. Twenty-two of 33 (66%) patients with 
Adenocarcinoma-in-situ had endometrial adenocarcinoma on subsequent hysterectomy 
versus 13 of 54 (24%) patients without Adenocarcinoma-in-situ (p= 0.0001). Myo-
invasive endometrial adenocarcinoma was present in 20 of 33 (61%) patients with 
Adenocarcinoma-in-situ versus 8 of the 54 (15%) patients without Adenocarcinoma-in-
situ (p=<0.0001). The depth of myometrial invasion in cases with myo-invasion was 24.5 
+ 19.4 % in patients with Adenocarcinoma-in-situ and12.8 + 8.5 % in patients without 
Adenocarcinoma-in-situ (p=0.05). Amongst patients younger than age of 50, 5 of the 7 
(71%) with Adenocarcinoma-in-situ had myo-invasive carcinoma versus 2 of the 13 
(15%) without Adenocarcinoma-in-situ (p=0.02). The likelihood of finding endometrial 
adenocarcinoma in subsequent hysterectomy in patients with complex atypical 
endometrial hyperplasia is significantly increased if Adenocarcinoma-in-situ is present in 
prior endometrial sampling. Endometrial adenocarcinomas in patients with 
Adenocarcinoma-in-situ are far more frequently myo-invasive, and invade to a greater 
depth than endometrial adenocarcinomas seen in patients without Adenocarcinoma-in-
situ. Use of Adenocarcinoma-in-situ terminology could lead to improved management of 
patients with complex atypical endometrial hyperplasia. 
 
 Background: The distinction of complex atypical endometrial hyperplasia from 
endometrial adenocarcinoma is frequently problematic1-11. Foci of back-to-back 
arrangement of glands or foci of cribriform arrangement of glands smaller than 2.1 mm in 
diameter are considered insufficient for the diagnosis of endometrial adenocarcinoma by 
some authors11, and sufficient to be diagnosed as endometrial adenocarcinoma by other 
authors10.  We have referred to these foci as endometrial Adenocarcinoma-in-situ in the 
past. We have previously shown that the presence of such foci in complex atypical 
endometrial hyperplasia is associated with increased risk of finding endometrial 
carcinoma in subsequent hysterectomy12. In the current study we have used a larger 
number of cases of complex atypical endometrial hyperplasia from 3 different centers to 
further evaluate this association.  
 
Design: Cases with the diagnosis of complex atypical endometrial hyperplasia on 
endometrial curettage/biopsy and subsequent hysterectomy were examined for the 
presence of Adenocarcinoma-in-situ. The cases were seen at New York University 
Medical Center, New York; North Broward Medical Center, Deerfield Beach, FL, and at 
Thomas Jefferson University Hospital, Philadelphia, PA. The cases were retrieved by 
searching for cases with the diagnosis of  complex endometrial hyperplasia in the 
computerized records in each facility. The cases were sequential and seen from 2003 to 
2006. Scant or otherwise sub-optimal specimens were excluded from the study. The 
presence or absence of Adenocarcinoma-in-situ was diagnosed at each facility based on 
review of the case by individual pathologists.  Cytologic features were not included as a 
criteria for exclusion of a case, but none of the cases had grade III nuclei. The review of 
biopsies was done blindly without knowledge of the hysterectomy findings. 
Hysterectomy diagnosis of record was used. 
 
Adenocarcinoma-in-situ was defined as foci of back to back arrangement of glands or 
foci of cribriform arrangement of glands composed of at least 4 glands and smaller than 
2.1 mm in diameter (figs. 1 to 3). Foci with marked glandular crowding, where stromal 
cells were readily identified between adjacent glands, were not considered 
Adenocarcinoma-in-situ. Artifactual cribriform arrangement of glands like appearance 
can be seen when there is squamous metaplasia or morule formation in endometrial 
glands, and these were also not included as Adenocarcinoma-in-situ (fig. 4). The size of 
the largest Adenocarcinoma-in-situ focus was noted in each case. Follow-up findings in 
the two groups of patients with and without Adenocarcinoma-in-situ were analyzed, 
including the presence or absence of carcinoma in the hysterectomy specimen, the grade 
of the carcinoma and the depth of myometrial invasion.  
 
Results: There were a total of 87 patients with complex atypical endometrial hyperplasia. 
The incidence of endometrial adenocarcinoma was 40% (35/87) and of myo-invasive 
carcinoma 32% (28/87) in subsequent hysterectomy in the entire group. All carcinomas 
were of endometrioid histology, and either grade I or II. Thirty-three patients (38%) had 
Adenocarcinoma-in-situ and 54 (62%) lacked Adenocarcinoma-in-situ. Twenty-two of 33 
(66%) patients with Adenocarcinoma-in-situ had endometrial adenocarcinoma on 
subsequent hysterectomy versus 13 of 54 (24%) patients without Adenocarcinoma-in-situ 
(p= 0.0001). Myo-invasive adenocarcinoma was present in 20 of 33 (61%) patients with 
Adenocarcinoma-in-situ versus 8 of the 54 (15%) patients without Adenocarcinoma-in-
situ (p <0.0001).  Myo-invasive carcinoma to a depth of 2 mm or more was present in 20 
of the 33 (61%) patients with AIS, versus 6 of the 54 (11%) patients without 
Adenocarcinoma-in-situ (p <0.0001). Myo-invasive carcinoma to a depth of 3 mm or 
more was present in 15 of the 33 (45%) patients with AIS, versus 2 of the 54 (4%) 
patients without Adenocarcinoma-in-situ (p <0.0001). The depth of myometrial invasion 
in cases with myo-invasion was 24.5 + 19.4 % in patients with Adenocarcinoma-in-situ 
and12.8 + 8.5 % in patients without Adenocarcinoma-in-situ (p=0.05). The absolute 
depth of invasion in myo-invasive cases was 4.8 + 3.5 mm in patients with 
Adenocarcinoma-in-situ and 2.1 + 1 mm in patients without Adenocarcinoma-in-situ 
(p=0.01). A depth of invasion of greater than 50% was seen in 3 of the 33 patients with 
AIS, but in none of the 54 patients without Adenocarcinoma-in-situ (p=0.05).  None of 
the carcinomas in either group were FIGO grade III. The larger size of the 
Adenocarcinoma-in-situ focus (>1 to <2.1 mm versus 1mm or smaller) was not predictive 
of subsequent carcinoma (p=0.68). The results are summarized in Table I.   
 
Patients younger than age of 50 
Amongst patients younger than age of 50, 5 of the 7 (71%) with Adenocarcinoma-in-situ 
had myo-invasive carcinoma versus 2 of the 14 (14%) without Adenocarcinoma-in-situ 
(p=0.02).  In all 5 patients that had myo-invasive carcinoma in the Adenocarcinoma-in-
situ group, the depth of invasion was 3 mm or greater. One of these patients had myo-
invasion of 1 cm, equal to 58% of myometrial thickness. The two patients in the group 
without Adenocarcinoma-in-situ had 1mm and 2mm depth of invasion respectively. The 
results are summarized in Table II. 
 
 
 
Discussion: 
 
The overall incidence of endometrial adenocarcinoma and myo-invasive endometrial 
adenocarcinoma on follow-up hysterectomy in the group of complex atypical endometrial 
hyperplasia patients reported here was similar to what has been reported in the literature6, 
7, 11, 13, 14
. We found that the presence of Adenocarcinoma-in-situ in complex atypical 
endometrial hyperplasia patients was associated with significantly greater likelihood of 
finding endometrial adenocarcinoma and myo-invasive endometrial adenocarcinoma on 
subsequent hysterectomy. Approximately two thirds of patients with Adenocarcinoma-in-
situ in endometrial curettage/biopsy have endometrial adenocarcinoma on subsequent 
hysterectomy versus about a quarter of those that lack Adenocarcinoma-in-situ. 
Endometrial adenocarcinomas in patients with Adenocarcinoma-in-situ are far more 
frequently myo-invasive, and invade to a greater depth than carcinomas seen in patients 
that have complex atypical endometrial hyperplasia without Adenocarcinoma-in-situ. 
 
There is considerable confusion in the literature as to where complex atypical 
endometrial hyperplasia ends and endometrial adenocarcinoma starts. The distinction of 
endometrial carcinoma from complex endometrial hyperplasia has generally been based 
on the criteria proposed by Kurman and Norris nearly 25 years ago11, 15, 16.  In these 
studies, the cut off for endometrial carcinoma was arbitrarily set at 2.1 mm lesional size 
showing features of “Stromal invasion”. However 7 of the 89 patients that lacked 
“Stromal invasion” also showed myo-invasive carcinoma in that study. It is unclear if any 
of these 7 patients with myoinvasive carcinoma had Adenocarcinoma-in-situ. This group 
without “Stromal invasion” included cases with complex atypical endometrial 
hyperplasia and “Carcinoma-in situ”, but separate follow up data for patients in complex 
atypical endometrial hyperplasia and “Carcinoma-in-situ” groups was not provided11. In 
other words, no data was presented regarding the outcome of patients that showed smaller 
foci of what was called “Stromal invasion”. Such lesions are diagnosed as complex 
atypical endometrial hyperplasia by some pathologists11, as endometrial adenocarcinoma 
by others10, and as endometrial adenocarcinoma can not be ruled out by yet others. King 
et al.17 examined a group of patients that they called “adenocarcinoma without stromal 
invasion” and found endometrial carcinoma in 28% (12/43) and myo-invasive carcinoma 
in 16% (7/43) of these patients on follow up hysterectomy. Longacre at al.18 have shown 
that glandular complexity captured by a pictorial architectural index, along with nuclear 
pleomorphism and prominence of the nucleoli are features most predictive for the 
presence of myo-invasive carcinoma in complex atypical endometrial hyperplasia. They 
also reported that extensive squamous differentiation and fibroblastic stroma do not 
contribute to prediction of myo-invasive endometrial carcinoma in subsequent 
hysterectomy. Hendrickson et al. did not find fibrous stroma in curettings from most 
patients with subsequent myo-invasive endometrial carcinoma19.    
 
We propose that foci of back to back glands or cribriform arrangement of glands smaller 
than 2.1 mm across be classified as Adenocarcinoma-in-situ. The term “Carcinoma-in-
situ” was mistakenly applied to eosinophilic metaplasia of the endometrium many years 
ago20 and is no longer used in that context. The concept that small foci of cribriform 
arrangement of glands be called “Carcinoma-in-situ” in the endometrium is not entirely 
new, and has been used in the past by Welch and Scully21, by Vellios22 and by Buehl et 
al23. This concept, however, was not strictly defined previously, its definition varied from 
author to author, and follow up data on these cases was not published. World Health 
Organization did not include any form of carcinoma in situ of endometrium in its 
classification24 because of lack of agreement on its definition21. In the current study, we 
have provided a strict definition for Adenocarcinoma in-situ of the endometrium, and 
documented its prognostic significance. 
 
The relationship between adenocarcinoma in situ diagnosed preoperatively and 
endometrial adenocarcinoma found in hysterectomy specimens is unclear. Some lesions 
might represent smaller foci of the same neoplasm whereas others might represent 
independent and incompletely developed, incipient invasive carcinomas or risk lesions. 
The following observations support the latter possibility in some cases. Multiple foci of 
Adenocarcinoma-in-situ can be seen without associated endometrial adenocarcinoma. 
Foci of Adenocarcinoma-in-situ are often fairly widely distributed, with intervening areas 
of complex atypical endometrial hyperplasia. We have also seen cases where the histo-
morphologic appearance of these foci varies, suggesting their independent origin from 
each other (fig. 5).   
 Although we prefer to use the term Adenocarcinoma-in-situ, a number of alternative 
terms could be potentially used for this lesion. These would include terms such as CAH 
type I and II, CAH type A and B, endometrial adenocarcinoma without stromal invasion, 
minimal carcinoma, micro-carcinoma, micro-invasive carcinoma, CAH with focal 
glandular confluence and “microscopic focus of adenocarcinoma”.  
 
Adenocarcinoma-in-situ of endometrium should not be confused with Endometrial 
Intraepithelial Carcinoma (EIC)25, which is an early form of uterine serous carcinoma 
characterized by growth of cells with high grade nuclei on the endometrial surface and in 
glands. These cells usually over-express p53. Cribriform arrangement of glands or back 
to back arrangement of glands is not seen in EIC. EIC usually arises in the background of 
an atrophic endometrium.  
 
Recognition of the substantial risk of myometrial invasion following a diagnosis of 
adenocarcinoma in situ should allow gynecologists and patients to make better informed 
decisions when conservative, non-surgical management is considered. In the current 
study only 2 of the 14 patients with complex atypical endometrial hyperplasia without 
Adenocarcinoma-in-situ age 50 or under had myo-invasion, which was 1mm and 2 mm 
respectively. Two had carcinoma confined to the endometrium, while 10 had no 
carcinoma. Thus these patients can be managed conservatively. In contrast 5 of the 7 
patients 50 or under with complex atypical endometrial hyperplasia with 
Adenocarcinoma-in-situ had myoinvasive carcinoma, and the depth of invasion in each of 
the 5 patients was 3 mm or more. One patient had 58% depth of invasion. Patients with 
complex atypical endometrial hyperplasia with Adenocarcinoma-in-situ may also be 
considered for lymph node sampling at hysterectomy if these lymph nodes are enlarged. 
 
In Summary, presence of Adenocarcinoma-in-situ should be looked for and reported by 
pathologists in endometrial biopsies showing complex atypical endometrial hyperplasia 
because of a significantly greater likelihood of finding endometrial adenocarcinoma and 
myo-invasive endometrial adenocarcinoma in subsequent hysterectomy if 
Adenocarcinoma-in-situ is present. 
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 Figure Legends: 
 
Figs.1 to 3. Examples of Adenocarcinoma-in-situ in cases of complex atypical 
endometrial hyperplasia. 1a, 2a, and 3a, are lower power views (H & E, x 40). 1b, 
2b, and 3b are the corresponding higher powers (H & E, x 200).    
 
Fig.4. A cribriform like appearance can be seen due to squamous morule formation in 
endometrial glands. This should not be confused with Adenocarcinoma-in-situ (H 
& E, x 200). 
 
Fig. 5. Occasionally, different foci of Adenocarcinoma-in-situ on the same slide have 
different morphologic features in the cells, suggesting their independent origin (H 
& E, x 200). 
 
 
 
  
  
  
 
Table Legends: 
 
Table 1.  
Endometrial adenocarcinoma and myo-invasion was much more likely to be found in  
subsequent hysterectomy in cases with complex atypical endometrial hyperplasia on 
endometrial biopsy if Adenocarcinoma-in-situ was present in prior endometrial biopsy. 
 
Table 2. 
In a subgroup of patients younger than 50 years of age, Endometrial adenocarcinoma and  
myo-invasion was much more likely to be found in subsequent hysterectomy in cases  
with Adenocarcinoma-in-situ in complex atypical endometrial hyperplasia on 
endometrial biopsy. 
 
 
